Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) Short Interest Down 52.9% in March

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) was the recipient of a large drop in short interest during the month of March. As of March 15th, there was short interest totalling 40,400 shares, a drop of 52.9% from the February 28th total of 85,700 shares. Based on an average daily trading volume, of 2,050,000 shares, the short-interest ratio is currently 0.0 days. Currently, 2.4% of the company’s stock are sold short.

Salarius Pharmaceuticals Stock Performance

Shares of Salarius Pharmaceuticals stock traded down $0.05 during mid-day trading on Friday, hitting $0.87. 31,696 shares of the stock were exchanged, compared to its average volume of 1,250,994. The company has a market capitalization of $1.50 million, a P/E ratio of -0.11 and a beta of 0.59. The company has a 50-day simple moving average of $1.56 and a 200 day simple moving average of $1.59. Salarius Pharmaceuticals has a 12 month low of $0.81 and a 12 month high of $7.20.

Salarius Pharmaceuticals (NASDAQ:SLRX) last posted its quarterly earnings data on Friday, March 21st. The company reported ($0.66) earnings per share for the quarter, topping the consensus estimate of ($2.31) by $1.65.

About Salarius Pharmaceuticals

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma.